<DOC>
	<DOCNO>NCT03011255</DOCNO>
	<brief_summary>Immunotherapy consider one promising approach treat cancer . Radiation therapy cornerstone treatment unresectable advanced esophageal cancer . Radiation-induced mutation gene identify new source tumor associate antigen use exon sequence peptide microarray technology . Epitope peptides target able induce peptide specific cytotoxic T lymphocytes ( CTL ) . In clinical trial , investigator evaluate efficacy safety peptide specific CTL therapy combination radiation therapy treat patient unresectable , advanced recurrent esophageal cancer .</brief_summary>
	<brief_title>Combination Radiation Therapy Peptide Specific CTL Therapy Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Esophageal Diseases</mesh_term>
	<criteria>1 . Patients must unresectable , locally advanced , recurrent disease esophageal cancer . Histologically confirm cancer esophagus . 2. measurable disease CT scan 3 . ECOG performance status 0 2 4 . Expected survival least 3months 5 . Laboratory value follow : Absolute neutrophil count ( ANC ) ≥ 1.5×109 White blood cell count ≥ 3×109/L Platelets ≥ 100×109/L Haemoglobin ( Hb ) ≥ 10g/dL ( patients'Hb correct &gt; 10g/dL treatment ) Adequate liver function ( within 1 week prior randomization ) Serum bilirubin ≤ 1.5× ULN Alanine aminotransferase/aspartate transaminase ( ALT / AST ) ≤ 2.5× ULN Alkaline phosphatase ( ALP ) ≤ 3× ULN 6 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Active uncontrolled infection 4 . Prior chemotherapy , radiation therapy immunotherapy 5 . Concurrent treatment steroid immunosuppressing agent 6 . Patient peptic ulcer disease 7 . Other malignancy within 5 year prior entry study , expect treat nonmelanoma skin cancer cervical carcinoma situ 8 . Disease central nervous system 9 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Peptide specific CTL</keyword>
	<keyword>Radiation</keyword>
</DOC>